Overview

Location [1]
1q25.2
Protein [2]
Tyrosine-protein kinase ABL2
Synonyms [1]
ABLL, ARG

ABL proto-oncogene 2, non-receptor tyrosine kinase (ABL2) is a gene that encodes a protein non-receptor tyrosine kinase. The protein functions in cytoskeletal rearrangements. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift insertions and deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

ABL2 is altered in 2.27% of all cancers with breast carcinoma, colorectal adenocarcinoma, melanoma, non-small cell lung carcinoma, and malignant glioma having the greatest prevalence of alterations [3].

ABL2 GENIE Cases - Top Diseases

The most common alterations in ABL2 are ABL2 Amplification (0.03%), ABL2 G1158S (0.00%), ABL2 A1075V (0.00%), ABL2 A1157V (0.00%), and ABL2 A234V (0.00%) [3].

ABL2 GENIE Cases - Top Alterations

Significance of ABL2 in Diseases

Acute Lymphoblastic Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

Acute Myeloid Leukemia +

Breast Carcinoma +

Malignant Solid Tumor +

Sarcoma +

Pancreatic Carcinoma +

Glioblastoma +

Bladder Carcinoma +

Colorectal Carcinoma +

Melanoma +

Non-Small Cell Lung Carcinoma +

Anaplastic Astrocytoma +

Chronic Myeloid Leukemia +

Chronic Myelomonocytic Leukemia +

Head And Neck Carcinoma +

Lymphoma +

Myelodysplastic Syndromes +

Ovarian Carcinoma +

Secondary Acute Myeloid Leukemia +

Therapy-Related Acute Myeloid Leukemia +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.